ArticleEuropean clinical respiratory journal2026
Impact of a follow-up visit on two-year mortality after severe exacerbation of COPD in Finland.
Article in European clinical respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Methodological considerations in evaluating post-AECOPD follow-up and long-term mortality.European clinical respiratory journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While guidelines recommend follow-up visits after an acute exacerbation of COPD (AECOPD), the optimal healthcare facility, timing and its effect on long-term mortality are not well known. Methods: In this retrospective case-control study, Finnish nationwide healthcare and mortality registries were linked to determine the association of a follow-up visit in secondary or primary care within 3 and 6 months after severe AECOPD on 2-year mortality. A conditional fixed-effects logistic regression analysis with 23 covariates was used. A nested case-control study design was applied with matching for age, sex, and multimorbidity in a 1:4 ratio. A time-varying Cox sensitivity analysis was performed to test result robustness. Results: In 2018, the Finnish prevalent COPD population consisted of 63 442 patients, of whom 10% experienced an AECOPD. After the AECOPD, 23% of the patients had a follow-up visit within 3 months. A follow-up in primary care wasn't associated with mortality (OR 1.06, 95% CI 0.90-1.24). However, patients with a follow-up in secondary care were at an increased mortality risk compared with controls without a follow-up (OR 1.62, 95% CI 1.37-1.92). In sensitivity analysis the effect lost statistical significance (HR 1.05, 95% CI 0.35-3.12) but a secondary care follow-up with an add-on primary care follow-up was associated with lower mortality (HR 0.56, 95% CI 0.51-0.61). The strongest predisposing factors were older age, comorbidities such as lung cancer, heart failure and atherosclerosis obliterans, home care, readmission, length of inpatient stay and prior health care use burden. By extending the follow-up time window to 6 months, the results remained largely similar. Conclusion: While we were able to quantify the effect of several patient characteristics on 2-year mortality after AECOPD, the effect of follow-up visits was unclear, likely due to residual confounding by indication. Further studies with even more robust methodology are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.